Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The goal of this observational study is to validate the Creyos online cognitive assessment platform in individuals with mild cognitive impairment, or remitted major depressive disorder. The main objectives of this research are: 1. To confirm the feasibility of administering the Creyos cognitive battery to older adults with Mild Cognitive Impairment MCI) or Major Depressive Disorder in remission (rMDD). 2. To determine whether the Creyos battery can detect changes in cognition that are predictive of changes on paper-and-pencil neuropsychological testing (gold standard) over up to five years. Participants will complete both in-person neuropsychological testing yearly as well as the Creyos online battery quarterly for up to 5 years, to allow us to compare performance on these two batteries over time.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Healthy Volunteers: t
View:

• Ability to read and communicate in English

• Availability of a study partner who has regular contact with the participant

Locations
Other Locations
Canada
Centre for Addiction and Mental Health
RECRUITING
Toronto
Contact Information
Primary
Benoit H. Mulsant, MD
benoit.mulsant@utoronto.ca
416-535-8501
Backup
Heather Brooks, PhD
heaher.brooks@camh.ca
416-535-8501
Time Frame
Start Date: 2026-01
Estimated Completion Date: 2029-01
Participants
Target number of participants: 150
Treatments
MCI
Individuals diagnosed with Mild Cognitive Impairment
Major Depressive Disorder in remission
Individuals with major depressive disorder in remission, with no active symptoms of depression
Control participants
Individuals with no history of psychiatric illness, not currently taking any psychotropic medications
Related Therapeutic Areas
Sponsors
Leads: Centre for Addiction and Mental Health
Collaborators: Krembil Foundation

This content was sourced from clinicaltrials.gov